MarketCap
Facebook
X
Telegram
Alkermes plc ROE Ratio | ALKS
Annual ROE Ratio Alkermes plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.29 | 25.06 | 29.58 | -15.17 | -4.33 | -10.39 | -18.11 | -11.89 | -13.13 | -17.23 | -17.28 | -2.15 | 2.63 | -13.32 | -11.62 | -9.6 | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.58 | -18.11 | -4.61 |
Quarterly ROE Ratio Alkermes plc
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.18 | 3.72 | 9.05 | 14.33 | 21.62 | 24.0 | 25.75 | 27.2 | 26.58 | 22.95 | 34.35 | 27.25 | 15.17 | 5.51 | -15.79 | -14.96 | -12.18 | -8.69 | -5.69 | -4.48 | -8.56 | -5.93 | -8.91 | -10.42 | -6.91 | -11.85 | -12.93 | -18.04 | -18.37 | -16.42 | -15.39 | -12.05 | -12.03 | -12.1 | -12.85 | -13.11 | -14.04 | -16.17 | -16.39 | -16.85 | -20.38 | -21.12 | -20.62 | -16.66 | -9.2 | -6.27 | -2.69 | -2.35 | -5.27 | -3.03 | -3.03 | -1.21 | -0.9 | 1.6 | 0.48 | 2.74 | -5.0 | -8.4 | -8.96 | -7.42 | -1.64 | -2.45 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 34.35 | -21.12 | -3.32 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-56.04 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
216.69 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-17.88 | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
-20.94 | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-139.05 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-170.94 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-125.3 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
269.84 | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-185.29 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.91 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
88.41 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-33.23 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-68.38 | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
-97.66 | $ 4.21 | 4.99 % | $ 653 M | USA |
 |
AbbVie
ABBV
|
-55.54 | $ 291.22 | 1.06 % | $ 515 B | USA |
 |
22nd Century Group
XXII
|
-32.07 | $ 1.56 | -19.17 % | $ 287 K | USA |
 |
Axon Enterprise
AXON
|
3.84 | $ 313.68 | -18.01 % | $ 24.5 B | USA |
 |
Biogen
BIIB
|
7.08 | $ 248.51 | 1.88 % | $ 36.4 B | USA |
 |
BioLineRx Ltd.
BLRX
|
-8.68 | $ 1.73 | -2.15 % | $ 4.26 B |  Israel |
 |
Theratechnologies
THTX
|
32.87 | - | - | $ 83.9 M | Canada |
 |
Exelixis
EXEL
|
36.21 | $ 69.55 | 1.22 % | $ 18.9 B | USA |
 |
Geron Corporation
GERN
|
-36.97 | $ 0.99 | 3.97 % | $ 660 M | USA |
 |
Gilead Sciences
GILD
|
37.48 | $ 166.9 | -0.4 % | $ 208 B | USA |
 |
Grifols, S.A.
GRFS
|
2.47 | $ 8.46 | -0.12 % | $ 5.75 B |  Spain |
 |
Alnylam Pharmaceuticals
ALNY
|
39.76 | $ 155.97 | -0.44 % | $ 20.4 B | USA |
 |
InflaRx N.V.
IFRX
|
-109.81 | $ 1.31 | -3.69 % | $ 88.1 M |  Germany |
 |
INmune Bio
INMB
|
-195.54 | $ 1.12 | -4.68 % | $ 27.7 M | USA |
 |
Insmed Incorporated
INSM
|
-172.78 | $ 114.55 | 5.32 % | $ 22.8 B | USA |
 |
Johnson & Johnson
JNJ
|
32.87 | $ 274.89 | 0.95 % | $ 662 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
-192.87 | - | -3.76 % | $ 3.47 M | USA |
 |
Lineage Cell Therapeutics
LCTX
|
-142.61 | $ 1.02 | 3.75 % | $ 235 M | USA |
 |
BioVie
BIVI
|
-92.27 | $ 1.33 | 9.92 % | $ 1.96 M | USA |
 |
Longeveron
LGVN
|
-400.07 | $ 1.82 | 6.43 % | $ 32 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-54.92 | - | 3.16 % | $ 1.9 M | USA |
 |
TCR2 Therapeutics
TCRR
|
-107.78 | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-46.9 | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Mustang Bio
MBIO
|
-20.16 | $ 0.39 | 0.15 % | $ 1.91 M | USA |
|
TFF Pharmaceuticals
TFFP
|
-222.05 | - | -60.05 % | $ 125 K | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 1.63 | 1.87 % | $ 2.68 M | Israel |
 |
Mesoblast Limited
MESO
|
-17.1 | $ 14.26 | 1.13 % | $ 17.2 B |  Australia |
 |
Mirum Pharmaceuticals
MIRM
|
-7.42 | $ 93.81 | 0.28 % | $ 4.71 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-597.64 | - | -15.15 % | $ 60.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-15.82 | - | - | $ 521 M | USA |
 |
Codexis
CDXS
|
-87.03 | $ 1.09 | 6.37 % | $ 95 M | USA |